Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Lenalidomide + Rituximab Hyaluronidase in R/R Indolent Non-Hodgkin's Lymphoma
NCT04447716Phase 1Active, not recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Oct 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by Thomas Jefferson University. Primary endpoint: Rate of dose-limiting toxicities at 56 days. Started Oct 2020; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04447716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447716.